AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Elicio Therapeutics Maintains Buy Rating with $12.50 Price Target Consensus
ByAinvest
Thursday, Aug 7, 2025 8:20 pm ET1min read
JonesTrading maintains a Buy rating for Elicio Therapeutics, with an analyst consensus of Moderate Buy and a price target consensus of $12.50. The company reported a quarterly GAAP net loss of $11.21 million, compared to $8.95 million last year. Soumit Roy, the analyst covering Elicio Therapeutics, has a 19.52% success rate on recommended stocks and an average return of -23.6%.
Elicio Therapeutics, Inc. (ELTX), a clinical-stage biotechnology company, has reported its second quarter 2025 financial results and provided updates on its cancer immunotherapy pipeline. The company's stock is currently trading under the ticker symbol ELTX.The Independent Data Monitoring Committee (IDMC) recommended continuing the ELI-002 7P Phase 2 study in pancreatic cancer without modifications, with final disease-free survival (DFS) analysis expected in Q4 2025. Financial highlights for Q2 2025 include a $10 million non-dilutive financing secured in June 2025. Research and development (R&D) expenses were $7.0 million, down from $8.2 million in Q2 2024, and the company reported a net loss of $10.6 million. The cash position of $22.1 million is expected to fund operations into Q1 2026, beyond the anticipated Phase 2 final analysis. Elicio plans to request an End-of-Phase 2 FDA meeting to finalize the regulatory strategy for ELI-002's pivotal Phase 3 trial following the final DFS analysis.
Elicio's lead product, ELI-002, is an AMP-powered therapeutic vaccine targeting mKRAS mutations in pancreatic and colorectal cancers. The company has already aligned with the FDA on key elements of the planned Phase 3 study design and maintains a cash runway extending into Q1 2026. Previous Phase 1 data showed promising results with 16.3-month median recurrence-free survival and 28.9-month median overall survival.
JonesTrading maintains a Buy rating for Elicio Therapeutics, with an analyst consensus of Moderate Buy and a price target consensus of $12.50. The company reported a quarterly GAAP net loss of $11.21 million, compared to $8.95 million last year. Soumit Roy, the analyst covering Elicio Therapeutics, has a 19.52% success rate on recommended stocks and an average return of -23.6%.
References:
[1] https://www.stocktitan.net/news/ELTX/
[2] https://www.stocktitan.net/news/ELTX/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet